Isaac Halickman, MD
Cardiovascular Disease · Voorhees, NJNPI 1437323250
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 198 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $545 and has fallen 55.0% since, to $246 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in NJ, where the typical reported total is $2,633.
Across 198 payments — averaging $12.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$457
- Pfizer$393
- Novartis$365
- Philips North America LLC$357
- Johnson & Johnson$272
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$88
- plus $488 from 18 others
Across 3 payments — averaging $3210.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$10K
What the payments were for
- Food & beverage$2,38198%
- Education$382%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 30 | $457 |
| Pfizer | 35 | $393 |
| Novartis | 25 | $365 |
| Philips North America LLC | 35 | $357 |
| Johnson & Johnson | 39 | $272 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $88 |
| Boehringer Ingelheim | 5 | $78 |
| Regeneron Healthcare Solutions, Inc. | 5 | $73 |
| E.r. Squibb & Sons, L.L.C. | 3 | $41 |
| Impulse Dynamics (USA) Inc. | 1 | $36 |
| Atricure, Inc. | 1 | $31 |
| Akcea Therapeutics, Inc. | 2 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Merck | 1 | $22 |
| Cvrx, Inc. | 1 | $21 |
| Watermark Medical, Inc. | 1 | $19 |
| Medtronic | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Vifor Pharma, Inc. | 1 | $14 |
| Boston Scientific | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Astellas Pharma US Inc | 1 | $12 |
| W. L. Gore & Associates, Inc. | 1 | $12 |
How this compares
$2,419 in reported general payments places this provider in the 45th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 20 | $475,697 |
| EliquisApixaban | 369 | $425,595 |
| XareltoRivaroxaban | 237 | $217,800 |
| EntrestoSacubitril/Valsartan | 113 | $149,971 |
| Repatha SureclickEvolocumab | 96 | $143,111 |
| Praluent PenAlirocumab | 65 | $75,455 |
| FarxigaDapagliflozin Propanediol | 42 | $55,505 |
| JardianceEmpagliflozin | 28 | $38,045 |
| BrilintaTicagrelor | 58 | $37,108 |
| VascepaIcosapent Ethyl | 13 | $12,228 |
| Metoprolol Succinate | 693 | $11,095 |
| Icosapent Ethyl | 28 | $10,801 |
| Rosuvastatin Calcium | 514 | $8,204 |
| Atorvastatin Calcium | 737 | $7,763 |
| Ezetimibe | 217 | $5,345 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $393 | $901,292389 claims |
| Johnson & JohnsonXarelto | $272 | $217,800237 claims |
| NovartisEntresto | $365 | $149,971113 claims |
| Boehringer IngelheimJardiance | $78 | $38,04528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Voorhees
- Elias IliadisVoorhees$158K
- Joseph ParrilloVoorhees$58K
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.